- $121.93bn
- $140.83bn
- £32.67bn
- 98
- 63
- 99
- 99
REG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Board and Committee Changes
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Transfer of Treasury Shares
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Jemperli positive trial in endometrial cancer
AnnouncementREG - GSK PLC - EMA file accepted for momelotinib
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK Capital B.V. GSK PLC - Publication of Final Terms of EMTN Notes
AnnouncementREG - GSK PLC - GSK publishes provisional 2023 dividend dates
AnnouncementREG - GlaxoSK Capital PLC GSK PLC - Publication of Supplementary EMTN Prospectus
AnnouncementREG - GSK PLC - Blenrep US Update
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSK Capital PLC GSK PLC - Publication of EMTN Supplementary Prospectus
AnnouncementREG - GlaxoSK Capital PLC GSK PLC - Final results of outstanding Notes Tender Offer
AnnouncementREG - GSK PLC - Block listing Interim Review
AnnouncementREG - GlaxoSK Capital PLC GSK PLC - Interim results of outstanding Notes Tender Offer
AnnouncementREG - GSK PLC - GSK Update: Zejula 2L in US
Announcement